L'Oreal Company ADR (LRLCY)

$82.58 0.22 (0.26%)

15:56 EST LRLCY Stock Quote Delayed 30 Minutes

15 European Dividend Aristocrats to Diversify Your Portfolio

By Derek English Jul 21, 2021

Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out.

3 Cosmetics Stocks to Freshen Up Your Holdings

Has Valeant Pharmaceuticals Intl Inc (VRX) Stock Finally Bottomed?

3 Stocks to Watch on Monday: Pandora Media Inc (P), GrubHub Inc (GRUB) and Nestle SA (ADR) (NSRGY)

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 69,779

Day's Range $81.66 - $82.58

52-Week Range $58.38 - $87.35

Dividend & Yield N/A (N/A)

LRLCY Stock Predictions, Articles, and L'Oreal Company ADR News

From InvestorPlace
From the Web

Valeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence

By James Brumley, InvestorPlace Feature Writer Jun 19, 2017

Valeant Pharmaceuticals (VRX) finds relief as John Paulson joins the board, but what can he really do to help VRX stock holders?

Don’t Buy the Valeant Pharmaceuticals Intl Inc (VRX) Stock Hype

By James Brumley, InvestorPlace Feature Writer Jun 8, 2017

VRX stock has emerged as one of Thursday's big winners, but it would be wise to crunch the numbers of the deal Valeant Pharmaceuticals just made.

Valeant Pharmaceuticals Intl Inc (VRX) Stock Won’t Keep This Rally Up

By Vince Martin, InvestorPlace Contributor May 8, 2017

Valeant earnings are due out Tuesday morning, but it would take a laundry list of good news to sustain the rally in VRX stock.

Will Valeant Shareholders Get ANYTHING? (VRX)

By Dana Blankenhorn, InvestorPlace Contributor Mar 14, 2017

Bill Ackman has abandoned Valeant (VRX), which has almost $30 billion in debt. VRX stock seems to be going through a slow liquidation.

The “New” Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Crock

By Will Ashworth, InvestorPlace Contributor Mar 7, 2017

Valeant Pharmaceuticals (VRX) might have a shiny new turnaround plan, but VRX stock is anything but new and improved.

Should You Buy Valeant Pharmaceuticals Intl Inc (VRX) Stock? 3 Pros, 3 Cons

By Ian Bezek, InvestorPlace Contributor Jan 24, 2017

Has Valeant Pharmaceuticals (VRX) turned the corner with its latest asset sales? Or is VRX stock still heading ever closer to zero?

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Breakup Gold

By Dana Blankenhorn, InvestorPlace Contributor Jan 10, 2017

Valeant Pharmaceuticals' (VRX) asset sales could be the start of a breakup. Speculators who get into VRX stock now can still reap rewards.

Natura & Co. could benefit from Aesop spinoff - BofA (NYSE:NTCO)

From Seeking Alpha Jan 31, 2023

Bank of America upgraded Natura & Co. (NTCO) to Buy from Neutral on Tuesday, advising clients that its exploration of strategic actions offers significant upside.Specifically,...

L’Oreal cut to Sell as RBC on China concerns (OTCMKTS:LRLCF)

From Seeking Alpha Dec 12, 2022

Aggressive expansion into China that has lifted L’Oreal (LRLCY) is turning into a headwind for the company, according to RBC Capital Markets.

Is Now the Right Time to Buy L'Oréal Stock?

From The Motley Fool Oct 26, 2022

The French cosmetics giant isn't too worried about inflation.

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May

From Benzinga Apr 1, 2022

Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

Alphabet Unit Verily, L'Oreal Collaborate On Skin Health: What You Need To Know

From Benzinga Jan 21, 2022

Alphabet, Inc.'s (NASDAQ: GOOGL) (NASDAQ: GOOG) subsidiary Verily, a precision health company, and L'Oréal S.A. (Pink: LRLCY) announced Thursday a strategic...

This Beauty-Care Company Is Working on a Turnaround. The Stock Is Looking Attractive.

From Barron's Sep 3, 2021

German personal-care products company Beiersdorf is back on track with growth in the first half of the year.